Life-threatening Infection in Humans: from Epidemiological Analysis to Molecular Genetics
This study, aims to identify and calculate the prevalence of cases potentially associated with congenital errors of immunity (ECI) among patients, hospitalized with infectious disease and carry out their clinical-laboratory characterization. Diagnoses of ECI are becoming increasingly common, by virtue of the continuing
| Condition(s) | Life-threatening Infection |
|---|---|
| Status | Recruiting |
| Study type | Observational |
| Summary | This study, aims to identify and calculate the prevalence of cases potentially associated with congenital errors of immunity (ECI) among patients, hospitalized with infectious disease and carry out their clinical-laboratory characterization. Diagnoses of ECI are becoming increasingly common, by virtue of the continuing discoveries of new disease-causing genes and an increasing understanding of the clinical signs and symptoms of these entities. The most important challenge still remains to achieve early diagnosis, which is essential for appropriate and individualized treatment that also takes into account the prognostic and genetic counseling aspect related to these disorders, which are associated with high rates of morbidity and mortality. Patients with nonimmunological diseases, secondary |
| Who can participate | Inclusion Criteria: * Obtained informed consent; * Otherwise healthy patient on admission Infectious episode: * life-threatening caused by known or unknown etiologic agent including viruses, bacteria, mycobacteria or mycetes (in case of lack of microbiologic isolate if clinical, laboratory, histopathologic and radiologic data, justify an infectious origin) * or caused by vaccine strains of attenuated vaccines such as Measles, Mumps, Rubella, Yellow Fever. * or caused by viruses, bacteria, mycobacteria or mycetes with features suggestive of congenital deficiency of immunity, the clinical pictures below refer to known conditions potentially associated with congenital errors of innate immunity Viral susceptibility: * ARDS caused by influenza virus type A, Sars-Cov2 * Life-threatening enterovi |
| Sex | All |
| Lead sponsor | IRCCS Azienda Ospedaliero-Universitaria di Bologna |
| Locations | Bologna, Bologna, Italy; Bologna, Bologna, Italy; Bologna, Bologna, Italy; Bologna, Bologna, Italy; Bologna, Bologna, Italy; Bologna, Bologna, Italy |
| Start date | 2024-10-01 |
| NCT ID | NCT06775496 |
| Official listing | https://clinicaltrials.gov/study/NCT06775496 |